文献速递类风湿关节炎

两项临床试验中早期类风湿关节炎与未分化关节炎两种糖皮质激素桥接策略的短期疗效与毒性比较

A comparison of short-term efficacy and toxicity of 2 glucocorticoid bridging strategies in 2 clinical trials in early rheumatoid and undifferentiated arthritis.
PubMed 文献 · Semin Arthritis Rheum · 2025-05-03

本研究比较两项临床试验:IMPROVED试验以甲氨蝶呤联合泼尼松60 mg/日起始、7周内减至7.5 mg/日(高剂量GC组),tREACH试验C组以甲氨蝶呤联合泼尼松15 mg/日起始、10周内减至零(低剂量GC组)。校正混杂因素后,低剂量GC组首次随访时DAS和HAQ显著更高,DAS缓解率和低疾病活动率更低,高剂量GC组不良事件更少。作者结论为高剂量GC初始治疗与更好的早期临床结局和更少早期副作用相关,但比较两项不同试验存在偏倚风险,结果需谨慎解读。

要点

  • 低剂量GC组首次随访DAS较高剂量GC组高0.62(95%CI 0.43;0.80),HAQ高0.28(95%CI 0.17;0.39)。
  • 低剂量GC组DAS缓解率63.4% vs 高剂量GC组28.9%,低疾病活动率80.6% vs 55.7%。
  • 高剂量GC组报告的不良事件更少,但比较两项不同试验存在偏倚风险。

核心结论

  • 在早期RA或UA患者中,高剂量GC作为初始治疗组成部分的研究与更好的早期临床结局和更少的早期副作用相关。
  • 作者指出,因比较两项不同临床试验而非开展单一试验存在偏倚风险,这些结果应谨慎解读。

研究设计与样本

  • 比较两项试验:IMPROVED试验以甲氨蝶呤联合泼尼松60 mg/日起始、7周内减至7.5 mg/日(高剂量GC研究);tREACH试验C组以甲氨蝶呤联合泼尼松15 mg/日起始、10周内减至零(低剂量GC研究)。
  • 经多重插补后,采用线性与逻辑回归模型比较3至4个月首次随访时的DAS、HAQ、DAS缓解(DAS<1.6)率和低疾病活动(DAS≤2.4)率,校正基线DAS/HAQ、年龄、性别、症状持续时间、ACPA阳性、BMI和损伤。

主要发现

  • 基线症状持续时间、DAS和HAQ可比,但低剂量GC研究C组更多患者满足2010年RA分类标准。
  • 校正混杂因素后,低剂量GC研究C组首次随访DAS较高剂量GC研究高0.62(95%CI 0.43;0.80),HAQ高0.28(95%CI 0.17;0.39)。
  • 低剂量GC研究C组DAS缓解率63.4% vs 高剂量GC研究28.9%,低疾病活动率80.6% vs 55.7%。
  • 高剂量GC研究报告的不良事件更少。

关键数值与推荐

  • DAS缓解定义为DAS<1.6,低疾病活动定义为DAS≤2.4。
  • 高剂量GC方案:泼尼松60 mg/日起始,7周内减至7.5 mg/日;低剂量GC方案:泼尼松15 mg/日起始,10周内减至零。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出,因比较两项不同临床试验而非开展单一试验存在偏倚风险,结果应谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare short-term outcomes of initial methotrexate therapy with higher or lower-dose glucocorticoid (GC) bridging in patients with early rheumatoid or undifferentiated arthritis. METHODS: We compared two trials: a 'higher-dose GC'-study starting with methotrexate and 60 mg/day prednisone, tapered in 7 weeks to 7.5 mg/day (IMPROVED trial) and a 'lower-dose GC'-study, starting with methotrexate and prednisone 15 mg/day tapered in 10 weeks to nil (arm C of the tREACH trial). After multiple imputation, we compared the DAS and HAQ, rates of DAS-remission (DAS<1.6) and low disease activity (DAS≤2.4) at the first follow-up visit after 3 to 4 months with linear and logistic regression models, adjusted for baseline DAS/HAQ, age, gender, symptom duration, ACPA positivity, BMI and damage. RESULTS: Baseline symptom duration, DAS and HAQ were comparable, but more patients in the lower-dose GC-study arm C fulfilled the 2010 criteria for RA. After correction for confounders, patients in the lower-dose GC-study arm C had a significantly higher DAS (0.62 higher (95 % CI 0.43; 0.80) and HAQ (0.28 higher (95 % CI 0.17; 0.39) at the first follow-up visit compared to patients in the higher-dose GC-study, and less often DAS-remission (63.4 % versus 28.9 %) and low disease activity (80.6 % versus 55.7 %). Fewer adverse events were reported in the higher-dose GC-study. CONCLUSION: In patients with early RA or UA, a study with higher dosed glucocorticoids as part of initial treatment was associated with significantly better early clinical outcomes compared to a study with lower dosed glucocorticoids, and fewer early side effects. These results should be interpreted with caution due to risk of bias when comparing two distinct clinical trials instead of performing one trial.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. van der Pol JA, Brilman EG, de Jong PHP, et al. A comparison of short-term efficacy and toxicity of 2 glucocorticoid bridging strategies in 2 clinical trials in early rheumatoid and undifferentiated arthritis. Semin Arthritis Rheum. 2025. PMID: 40367657. doi:10.1016/j.semarthrit.2025.152748

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。